New Report sheds light on the Cervical Cancer - Pipeline Review, H1 2017

Cervical Cancer - Pipeline Review, H1 2017 is a new market research publication announced by Reportstack. This report provides an overview of the Cervical Cancer (Oncology) pipeline landscape.

Cervical cancer occurs when abnormal cells on the cervix grow out of control. Most cervical cancer is caused by a virus called human papillomavirus, or HPV. Abnormal cervical cell changes rarely cause symptoms. Symptoms of cervical cancer may include abnormal vaginal bleeding, such as bleeding after sex (vaginal intercourse), bleeding after menopause, bleeding and spotting between periods, and having longer or heavier (menstrual) periods than usual. Treatment options include surgery, radiation therapy, chemotherapy or a combination of methods.

Complete report available @ Cervical Cancer - Pipeline Review, H1 2017

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Cervical Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Cervical Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cervical Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Cervical Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 6, 32, 32, 47, 4 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 5, 2, 11 and 4 molecules, respectively.

Cervical Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Cervical Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Cervical Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Cervical Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Cervical Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Cervical Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cervical Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cervical Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

Abion Inc Abivax SA Admedus Ltd Advaxis Inc Advenchen Laboratories LLC Agenus Inc AntiCancer Inc Antigen Express Inc Arbor Vita Corp ArQule Inc Asana BioSciences LLC AstraZeneca Plc Atara Biotherapeutics Inc AVEO Pharmaceuticals Inc BeiGene Ltd Bioleaders Corp Biomics Biotechnologies Co Ltd Blirt SA Boehringer Ingelheim GmbH Bristol-Myers Squibb Company Cancer Research Technology Ltd Cell Medica Ltd Cellceutix Corp Celleron Therapeutics Ltd Coherus BioSciences Inc Critical Outcome Technologies Inc Cytori Therapeutics Inc CZ BioMed Corp DelMar Pharmaceuticals Inc Dr. Reddy's Laboratories Ltd Eisai Co Ltd Etubics Corp Eureka Therapeutics Inc EyeGene Inc F. Hoffmann-La Roche Ltd Formune SL GamaMabs Pharma SA Gene Techno Science Co Ltd Genexine Inc Genmab A/S Genor BioPharma Co Ltd GlaxoSmithKline Plc Glycostem Therapeutics BV Glycotope GmbH Gradalis Inc Immune Therapeutics Inc Immunomedics Inc Immunovaccine Inc Insys Therapeutics Inc ISA Pharmaceuticals BV Johnson & Johnson Juno Therapeutics Inc Kaketsuken KK Karyopharm Therapeutics Inc Kite Pharma Inc Lion Biotechnologies Inc LondonPharma Ltd Mabion SA MedImmune LLC Merck & Co Inc Mycenax Biotech Inc Nanotherapeutics Inc Nektar Therapeutics NeoImmuneTech Inc Oncobiologics Inc Oryx GmbH & Co KG PDS Biotechnology Corp Pfizer Inc Pharma Mar SA Psicofarma SA de CV Puma Biotechnology Inc Rexahn Pharmaceuticals Inc Richter Gedeon Nyrt Samyang Holdings Corp Sanofi Seattle Genetics Inc Selecta Biosciences Inc Shantha Biotechnics Pvt Ltd Sirnaomics Inc Sun Pharma Advanced Research Company Ltd Taiho Pharmaceutical Co Ltd Tessa Therapeutics Pte Ltd Theravectys SA THEVAX Genetics Vaccine USA Inc Tomegavax Inc UbiVac LLC VLPbio Wellstat Biologics Corp Zeria Pharmaceutical Co Ltd Zydus Cadila Healthcare Ltd

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

ReportstackMarket Research

###